Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in advanced pancreatic adenocarcinoma
NCT00470535Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib in pancreatic adenocarcinoma (PDAC), sponsored by Roswell Park Comprehensive Cancer Center. Started Jan 2007; status: terminated.
02
Drugs
erlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00470535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00470535.